Pricing in the market for anticancer drugs

Journal of Economic Perspectives

Volumn 29, Issue 1, 2015, Pages 139-162

  Howard, David H ^a   Bach, Peter B ^b   Berndt, Ernst R ^c   Conti, Rena M ^d  

^a EMORY UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

COMMERCIAL PHENOMENA; DRUG COST; DRUG INDUSTRY; ECONOMICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LIFE EXPECTANCY; MEDICAID; MEDICARE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTINEOPLASTIC AGENTS; COMMERCE; DRUG COSTS; DRUG INDUSTRY; HEALTH CARE SECTOR; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LIFE EXPECTANCY; MEDICAID; MEDICARE; UNITED STATES;

EID: 84922419758     PISSN: 08953309     EISSN: 19447965     Source Type: Journal    
DOI: 10.1257/jep.29.1.139     Document Type: Article

References (79)

1. Akscin, John, Thomas R. Barr, and Elaine L. Towle. 2007. "Key Practice Indicators in Office-Based Oncology Practices: 2007 Report on 2006 Data." Journal of Clinical Oncology 3(4): 200-203.
2. Anand, Geeta. 2007. "Prescribing Caution: From Wall Street, a Warning About Cancer-Drug Prices; Morgan Stanley Analyst Creates Stir in Industry as He Sees a Backlash." Wall Street Journal, March 15. http://online.wsj.com/news/articles/SB117391934158537592.
3. Bach, Peter B. 2009. "Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs." New England Journal of Medicine 360(6): 626-33.
4. Bach, Peter B., Leonard B. Saltz, and Robert E. Wittes. 2012. "In Cancer Care, Cost Matters." New York Times, October 14.
5. Berndt, Ernst R., Linda Bui, David R. Reiley, and Glen L. Urban. 1995. "Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market." American Economic Review 85(2): 100-105.
6. Berndt, Ernst R., David M. Cutler, Richard G. Frank, Zvi Griliches, Joseph P. Newhouse, and Jack E. Triplett. 2000. "Medical Care Prices and Output." Chap. 3 in Handbook of Health Economics, Vol. 1A, edited by Anthony C. Culyer and Joseph P. Newhouse. Amsterdam: Elsevier Science.
7. Berndt, Ernst R., and Joseph P. Newhouse. 2012. "Pricing and Reimbursement in US Pharmaceutical Markets." Chap. 8 in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson. Oxford University Press.
8. Biotechnology Industry Organization. 2013. The 340B Drug Discount Program. https://www.bio.org/articles/340b-drug-discount-program.
9. Budish, Eric, Benjamin N. Roin, and Heidi Williams. 2013. "Do Fixed Patent Terms Distort Innovation? Evidence from Cancer Clinical Trials." NBER Working Paper 19430.
10. Busch, Susan H., Ernst R. Berndt, and Richard G. Frank. 2001. "Creating Price Indexes for Measuring Productivity in Mental Health Care." Chap. 5 in Frontiers in Health Policy Research, vol. 4, edited by Alan M. Garber. Cambridge, MA: MIT Press for the National Bureau of Economic Research.
11. Cavalli, Franco. 2013. "An Appeal to World Leaders: Stop Cancer Now." The Lancet 381(9865): 425-26.
12. Caves, Richard E., Michael D. Whinston, and Mark A. Hurwitz. 1991. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry." Brookings Papers on Economic Activity: Microeconomics 1-48.
13. Center for Medicare & Medicaid Services. 2014. "CMS Proposes Program Changes for Medicare Advantage and Prescription Drug Benefit Programs for Contract Year 2015 (CMS-4159-P)." January 6. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-Sheets/2014-Fact-sheets-items/2014-01-06.html.
14. CenterWatch. 2014. FDA Approved Drugs for Oncology. http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/.
15. Chen, Jie, and John A. Rizzo. 2012. "Pricing Dynamics and Product Quality: The Case of Antidepressant Drugs." Empirical Economics 42(1): 279-300.
16. Cockburn, Iain M., and Aslam H. Anis. 2001. "Hedonic Analysis of Arthritis Drugs." Chap. 11 in Medical Care Output and Productivity, edited by David Cutler and Ernst R. Berndt. University of Chicago Press.
17. Conti, Rena M., and Peter B. Bach. 2013. "Cost Consequences of the 340B Drug Discount Program." JAMA: Journal of the American Medical Association 309(19): 1995-96.
18. Conti, Rena M., Arielle C. Bernstein, Victoria M. Villaflor, Richard L. Schilsky, Meredith B. Rosenthal, and Peter B. Bach. 2013. "Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists." Journal of Clinical Oncology 31(9): 1134-39.
19. Conti, Rena M., Meredith B. Rosenthal, Blase N. Polite, Peter B. Bach, and Ya-Chen Tina Shih. 2012. "Infused Chemotherapy Use in the Elderly After Patent Expiration." American Journal of Managed Care 18(5): e173-78.
20. Dendreon. 2014. Patient Access. http://www.dendreon.com/patient-resources/patient-access/.
21. Drug Discount Monitor. 2014. "340B Sales Totaled $7.5 Billion in 2013, Apexus Says." February 14. Link (for subscribers only): http://drugdiscountmonitor.com/2014/02/340b-sales-totaled-7-5-billion-in-2013-apexus-says/.
22. Experts in Chronic Myeloid Leukemia. 2013. "The Price of Drugs for Chronic Myeloid Leukemia (CML) is a Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Large Group of CML Experts." Blood 121(22): 4439-42.
23. Fleck, Leonard M. 2013. "Just Caring: Can We Afford the Ethical and Economic Costs of Circumventing Cancer Drug Resistance?" Journal of Personalized Medicine 3(3): 124-43.
24. Frank, Richard G., and David S. Salkever. 1997. "Generic Entry and the Pricing of Pharmaceuticals." Journal of Economics and Management Strategy 6(1): 75-90.
25. Frey, Bruno S., and Werner W. Pommerehne. 1993. "On the Fairness of Pricing - An Empirical Survey among the General Population." Journal of Economic Behavior and Organization 20(3): 295-307.
26. Gingrich, Newt. 2009. "Trust the Government." Human Events, August 12. http://humanevents.com/2009/08/12/trust-the-government/.
27. Goldman, Dana P., Anupam B. Jena, Darius N. Lakdawalla, Jennifer L. Malin, Jesse D. Malkin, and Eric Sun. 2010. "The Value of Specialty Oncology Drugs." Health Service Research 45(1): 115-32.
28. Goldman, Dana P., Geoffrey F. Joyce, Grant Lawless, William H. Crown, and Vincent Willey. 2006. "Benefit Design and Specialty Drug Use." Health Affairs 25(5): 1319-31.
29. Griffith, Victoria. 2004. "Pricing Weighs on Cancer Treatments." Financial Times, June 3.
30. Hall, Stephen S. 2013. "The Cost of Living." New York Magazine, October 20. http://nymag.com/news/features/cancer-drugs-2013-10/.
31. Hirth, Richard A, Michael E. Chernew, Edward Miller, A. Mark Fendrick, and William G. Weissert. 2000. "Willingness to Pay for a Quality-Adjusted Life Year: In Search of a Standard." Medical Decision Making 20(3): 332-42.
32. Howard, David H. 2014. "Drug Companies'Patient-Assistance Programs - Helping Patients or Profits?" New England Journal of Medicine 371(2): 97-99.
33. Howard, David H., John Kauh, and Joseph Lipscomb. 2010. "The Value of New Chemotherapeutic Agents for Metastatic Colorectal Cancer." Archives of Internal Medicine 170(6): 537-42.
34. Howard, David H., Carolyn Kenline, Hillard M. Lazarus, Charles F. LeMaistre, Richard T. Maziarz, Philip L. McCarthy Jr., Susan K. Parsons, David Szwajcer, James Douglas Rizzo, and Navneet S. Majhail. 2011. "Abandonment of High Dose Chemotherapy/Hematopoietic Cell Transplants for Breast Cancer." Health Services Research 46(6, Part 1): 1762-77.
35. Howard, David H., Nicole A. Molinari, and Kenneth E. Thorpe. 2004. "National Estimates of Medical Costs Incurred by Nonelderly Cancer Patients." Cancer 100(5): 883-91.
36. Hutchison, Courtney. 2010. "Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?" ABC News, July 29. http://abcnews.go.com/Health/ProstateCancerNews/provenge-cancer-vaccine-months-life-worth-100k/story?id=11269159.
37. IMS Institute for Healthcare Informatics. 2014. "Innovation in Cancer Care and Implications for Health Systems: Global Oncology Trend Report." Available at: http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=f8d4df7a5e8b5410VgnVCM10000076192ca2RCRD.
38. InsideHealthPolicy. 2014. "MedPAC Explores Fixes to Part B Drug Payment Policy, Calls Current System 'Perverse Incentive.'" November 12. http://www.pipcpatients.org/pipc-admin/pdf/cde114-MedPAC%20Explores%20Fixes%20To%20Part%20B%20Drug%20Payment%20Policy.pdf.
39. Jacobson, Mireille, Craig C. Earle, Mary Price, and Joseph P. Newhouse. 2010. "How Medicare's Payment Cuts for Cancer Chemotherapy Drugs Changed Patterns of Treatment." Health Affairs 29(7): 1391-99.
40. Jacobson, Mireille, A. James O'Malley, Craig C. Earle, Juliana Pakes, Peter Gaccione, and Joseph P. Newhouse. 2006. "Does Reimbursement Influence Chemotherapy Treatment for Cancer Patients?" Health Affairs 25(2): 437-43.
41. Kahneman, Daniel, Jack L. Knetsch, and Richard H. Thaler. 1986. "Fairness as a Constraint on Profit Seeking: Entitlements in the Market." American Economic Review 76(4): 728-41.
42. Kaiser Family Foundation and Health Research & Educational Trust. 2013. Employer Health Benefits: 2013 Annual Survey. Washington, DC.
43. Kalyanaram, Gurumurthy, and John D. C. Little. 1994. "An Empirical Analysis of Latitude of Price Acceptance in Consumer Package Goods." Journal of Consumer Research 21(3): 408-18.
44. Kantarjian, Hagop M., Tito Fojo, Michael Mathisen, and Leonard A. Zwelling. 2013. "Cancer Drugs in the United States: Justum Pretium - The Just Price." Journal of Clinical Oncology 31(28): 3600-3604.
45. Lakdawalla, Darius N., John A. Romley, Yuri Sanchez, J. Ross Maclean, John R. Penrod, and Tomas Philipson. 2012. "How Cancer Patients Value Hope and the Implications for Cost-Effectiveness Assessments of High-Cost Cancer Therapies." Health Affairs 31(4): 676-82.
46. Landsem, Hope. 2013. "Rationing Health Care in Oregon." Wall Street Journal, August 8. http://online.wsj.com/news/articles/SB10001424127887324522504579000560184822956.
47. Lichtenberg, Frank R. 2009a. "The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978-2004." Economics of Innovation and New Technology 18(5): 407-28.
48. Lichtenberg, Frank R. 2009b. "International Differences in Cancer Survival Rates: The Role of New Drug Launches." International Journal of Healthcare Technology and Management 10(3): 138-55.
49. Lu, Z. John, and William S. Comanor. 1998. "Strategic Pricing of New Pharmaceuticals." Review of Economics and Statistics 80(1): 108-18.
50. Lucarelli, Claudio, and Sean Nicholson. 2009. "A Quality-Adjusted Price Index for Colorectal Cancer Drugs." NBER Working Paper 15174.
51. Malin, Jennifer L., Jane C. Weeks, Arnold L Potosky, Mark C. Hornbrook, and Nancy L. Keating. 2013. "Medical Oncologists' Perceptions of Financial Incentives in Cancer Care." Journal of Clinical Oncology 31(5): 530-35.
52. Marcus, Amy Dockser. 2004. "Price Becomes Factor in Cancer Treatment." Wall Street Journal, September 7. http://online.wsj.com/news/articles/SB109450779986210547.
53. Mas, Alexandre. 2006. "Pay, Reference Points, and Police Performance." Quarterly Journal of Economics 121(3): 783-821.
54. Maxwell, Sarah. 2002. "Rule-Based Price Fairness and Its Effect on Willingness to Purchase." Journal of Economic Psychology 23(2): 191-212.
55. National Cancer Institute. 2014. "Cancer Drug Information." A webpage: http://www.cancer.gov/cancertopics/druginfo/alphalist.
56. National Comprehensive Cancer Network. 2010. "Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed." October 18. http://www.nccn.org/about/news/newsinfo.aspx?NewsID=259.
57. Neumann, Peter J. 2005. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford University Press.
58. Newhouse, Joseph P. 1992. "Medical Care Costs: How Much Welfare Loss?" Journal of Economic Perspectives 6(3): 3-21.
59. Niraula, Saroj, Bostjan Seruga, Alberto Ocana, Tiffany Shao, Robyn Goldstein, Ian F. Tannock, and Eitan Amir. 2012. "The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs." Journal of Clinical Oncology 30(24): 3012-19.
60. PhRMA (Pharmaceutical Research and Manufacturers of America). 2014. "Medicines in Development." A webpage: http://www.phrma.org/innovation/meds-in-development.
61. Piron, Robert, and Luis Fernandez. 1995. "Are Fairness Constraints on Profit-Seeking Important?" Journal of Economic Psychology 16(1): 73-96.
62. Raborn Martin L., Elise M. Pelletier, Daniel B. Smith, and Carolina M. Reyes. 2012. "Patient Out-of-Pocket Payments for Oral Oncolytics: Results from a 2009 US Claims Data Analysis." American Journal of Managed Care 18(5 No. 2): SP57-64.
63. Reekie, W. Duncan. 1978. "Price and Quality Competition in the United States Drug Industry." Journal of Industrial Economics 26(3): 223-37.
64. Romley, John A, Yuri Sanchez, John R. Penrod, and Dana P. Goldman. 2012. "Survey Results Show That Adults Are Willing to Pay Higher Insurance Premiums for Generous Coverage of Specialty Drugs." Health Affairs 31(4): 683-90.
65. Schrag, Deborah. 2004. "The Price Tag on Progress - Chemotherapy for Colorectal Cancer." New England Journal of Medicine 351(4): 317-19.
66. Seabury, Seth A., Dana P. Goldman, J. Ross Maclean, John R. Penrod, and Darius N. Lakdawalla. 2012. "Patients Value Metastatic Cancer Therapy More Highly Than is Typically Shown Through Traditional Estimates." Health Affairs 31(4): 691-99.
67. Silber, Judy. 2005. "Onyx Gets OK for Kidney Cancer Drug." Contra Costa Times, December 21.
68. Snider, Julia Thornton, John A. Romley, William B. Vogt, and Tomas J. Philipson. 2012. "The Option Value of Innovation." Forum for Health Economics & Policy 15(2).
69. Sun, Eric, Anupam B. Jena, Darius Lakdawalla, Carolina Reyes, Tomas J. Philipson, and Dana Goldman. 2010. "The Contributions of Improved Therapy and Early Detection to Cancer Survival Gains, 1988-2000." Forum for Health Economics & Policy 13(2).
70. Suslow, Valerie Y. 1996. "Measuring Quality Change in Pharmaceutical Markets: Hedonic Price Indexes for Anti-Ulcer Drugs." Chap. 4 in Competitive Strategies in the Pharmaceutical Industry, edited by Robert B. Helms. Washington, DC: American Enterprise Institute.
71. Szabo, Liz. 2004 "Price of Cancer Drugs Called 'Mind-Boggling.'" USA Today, July 21. http://usatoday30.usatoday.com/news/health/2004-07-21-cancer-usat-x.htm.
72. Thaler, Richard. 1985. "Mental Accounting and Consumer Choice." Marketing Science 4(3): 199-214.
73. Trusheim, Mark R., and Ernst R. Berndt. 2012. "The Segmentation of Therapeutic Populations in Oncology." Health Management, Policy and Innovation 1(1): 19-34.
74. US Food and Drug Administration. 2014a. Table of Pharmacogenomic Biomarkers in Drug Labeling. http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm.
75. US Food and Drug Administration. 2014b. "Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review." http://www.fda.gov/ForPatients/Approvals/Fast/default.htm.
76. US General Accounting Office. 2011. Manufacturer Discounts in the 340B Program Offer Benefits, But Federal Oversight Needs Improvement. Washington, D.C.
77. Weeks, Jane C., Paul J. Catalano, Angel Cronin, Matthew D. Finkelman, Jennifer W. Mack, Nancy L. Keating, and Deborah Schrag. 2012 "Patients'Expectations about Effects of Chemotherapy for Advanced Cancer." New England Journal of Medicine 367(17): 1616-25.
78. Wittes, Robert E. 2004. "Cancer Weapons, Out of Reach." Washington Post. June 15. http://www.washingtonpost.com/wp-dyn/articles/A42035-2004Jun14.html.
79. Woodward, Rebecca M., Martin L. Brown, Susan T. Stewart, Kathleen A. Cronin, and David M. Cutler. 2007. "The Value of Medical Interventions for Lung Cancer in the Elderly: Results from SEER-CMHSF." Cancer 110(11): 2511-18.